Cosentyx (secukinumab) vs. the other biologics you might consider for psoriasis, psoriatic arthritis (PsA), or ankylosing spondylitis (AS)
| What you’re looking for | How Cosentyx measures up | How the alternatives stack up |
|--------------------------|--------------------------|------------------------------|
| Rapid, deep skin clearance | In the pivotal ERASURE and FIXTURE studies, 70–80 % of patients achieved PASI‑90 (90 % clearance) and 50–60 % achieved PASI‑100 (complete clearance) within 12 weeks. The effect is sustained for at least 5 years in extension data. | Ixekizumab (another IL‑17A blocker) shows very similar rates; ustekinumab (IL‑12/23) and guselkumab/tildrakizumab (IL‑23) also achieve PASI‑90 in ~60 % but usually a bit later. TNF inhibitors (adalimumab, etanercept, infliximab) reach PASI‑90 in ~40–50 % after 12 weeks. |
| Joint improvement (PsA/AS) | Secukinumab consistently improves the ASDAS score (ankylosing spondylitis disease activity score) and the MDA (minimal disease activity) criteria for PsA in the MEASURE and COAST trials, with ~65 % of PsA patients achieving MDA by week 24. | Ixekizumab and guselkumab also improve joint disease, but the data are slightly more limited. TNF inhibitors are first‑line for PsA/AS, but many patients lose response or cannot tolerate them; secukinumab can be a useful next step. |
| Safety profile (infections, TB, malignancy) | Secukinumab has lower rates of serious bacterial infections and does not increase the risk of latent TB reactivation the way TNF inhibitors do. The most common adverse event is mild, non‑serious oral candidiasis (≤10 %). Long‑term studies (up to 5 years) have not shown an excess of malignancies. | TNF inhibitors carry a small but real risk of TB reactivation, opportunistic infections, and some data suggest a slightly higher risk of certain malignancies (especially lymphoma). Ustekinumab and IL‑23 blockers have a good safety record but are not associated with as low a candidiasis risk. |
| Convenience & adherence | 300 mg subcutaneous (SC) injection once every 4 weeks after the first 4 weekly loading doses. No need for IV infusion or a clinic visit for administration, so it’s easy to incorporate into a busy life. | Ixekizumab is also SC every 4 weeks (after a 2‑dose loading), but its injection volume is larger (40 mg). TNF inhibitors can be SC (adalimumab) or subcutaneous injection or IV infusion (infliximab), so scheduling can be more variable. IL‑23 blockers are also SC every 4–8 weeks. |
| Immunogenicity | Very low rates of anti‑drug antibodies (≤1 %) – this keeps efficacy consistent over time. | IL‑17 inhibitors (ixekizumab) also have low immunogenicity. TNF inhibitors have higher antibody rates, which can reduce effectiveness. |
| Patient‑specific considerations | • Good for patients who have failed or are intolerant to TNF inhibitors.
• Preferred in patients with history of latent TB because secukinumab does not reactivate TB.
• Less likely to trigger demyelinating events than TNF inhibitors. | • TNF inhibitors are still the first choice for severe inflammatory bowel disease that co‑exists with PsA.
• Ustekinumab/IL‑23 inhibitors are often chosen when a patient has a strong family history of malignancy or when a clinician wants to avoid IL‑17 inhibition. |
---
Why a clinician might pick Cosentyx over the others
1. Best evidence for rapid, complete skin clearance – 5‑year data show a sustained high proportion of patients reaching PASI‑100.
2. Strong joint‑response data – a solid track record in PsA and AS, making it a “dual‑action” drug.
3. Fewer infection concerns – no TB reactivation, mild candidiasis is manageable.
4. Convenient SC dosing – one 300 mg shot every month after the first 4 weekly shots.
5. Low immunogenicity – less chance of loss of response over time.
6. Good for patients who previously tried TNF blockers – many lose efficacy or have side‑effects on TNF therapy; secukinumab often works when TNF agents fail.
---
Caveats
- Individual response varies – what works for one person may not for another.
- Cost and insurance – all biologics are pricey; formulary placement may dictate what’s first available.
- Special populations – e.g., patients with chronic inflammatory bowel disease may be better served by TNF inhibitors or ustekinumab.
- Pregnancy & breastfeeding – data are limited; discuss risks with a specialist.
---
Bottom line: If you’re looking for a biologic that delivers fast, deep skin clearance, good joint control, a strong safety record for infections, and a simple monthly shot, Cosentyx is often the preferred choice once TNF inhibitors have been ruled out or have failed. Always tailor the decision to your specific clinical picture, comorbidities, and personal preferences.